Table 2.
Individual components of GerdQ scores at baseline and at the follow-up visit
| Treatment group* | ||
|---|---|---|
| Control | Implementation | |
| Heartburn | ||
| Number of patients | 900 | 834 |
| Baseline | 2.08 (1.00) | 2.21 (0.86) |
| Follow-up | 0.92 (0.93) | 0.67 (0.79) |
| Change (follow-up – baseline) | −1.16 (1.22) | −1.54 (1.10) |
| Regurgitation | ||
| Number of patients | 900 | 834 |
| Baseline | 1.64 (1.06) | 1.63 (0.99) |
| Follow-up | 0.75 (0.87) | 0.49 (0.70) |
| Change (follow-up – baseline) | −0.89 (1.10) | −1.14 (1.07) |
| Difficulty in sleep | ||
| Number of patients | 900 | 834 |
| Baseline | 1.40 (1.06) | 1.49 (1.03) |
| Follow-up | 0.52 (0.80) | 0.34 (0.61) |
| Change (follow-up – baseline) | −0.89 (1.12) | −1.15 (1.07) |
| Additional OTC medication | ||
| Number of patients | 900 | 834 |
| Baseline | 1.11 (1.20) | 1.36 (1.19) |
| Follow-up | 0.42 (0.83) | 0.29 (0.66) |
| Change (follow-up – baseline) | −0.69 (1.27) | −1.07 (1.26) |
Values are means (SD).
*
Control = usual care; implementation = structured treatment pathway. GerdQ, Gastro-oesophageal Reflux Disease Questionnaire; OTC, over the counter.